<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04353778</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 18-2812</org_study_id>
    <secondary_id>1R01DK122853-01A1</secondary_id>
    <nct_id>NCT04353778</nct_id>
  </id_info>
  <brief_title>Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV</brief_title>
  <acronym>EVA</acronym>
  <official_title>Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study team's prior research has shown that dysfunction of a specific nerve, called the&#xD;
      vagus nerve, is associated with small intestinal bacterial overgrowth (SIBO), and that SIBO&#xD;
      is associated with signs of inflammation in the blood of people living with HIV (PLWH). This&#xD;
      research will explore pathways linking vagal dysfunction to inflammation in HIV, focusing on&#xD;
      the gastrointestinal tract, and study whether a medication called pyridostigmine and&#xD;
      stimulation of the vagus nerve are beneficial therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives Aim 1: To elucidate mechanisms linking VD, SIBO and chronic inflammation in PLWH.&#xD;
      PLWH (N=150) will undergo autonomic function tests (AFTs) for VD, hydrogen/methane breath&#xD;
      testing (HBT) for SIBO, Wireless Motility Capsule (WMC, SmartPill) testing for GI transit&#xD;
      times and pH measurements, blood draw for quantification of inflammatory mediators, and&#xD;
      collection of stool samples and oral swabs for characterization of the GI microbiome.&#xD;
&#xD;
      Hypothesis 1a (primary): The relationship between VD and SIBO in HIV is mediated by prolonged&#xD;
      small bowel transit time (SBTT) and hypochlorhydria.&#xD;
&#xD;
      Hypothesis 1b (exploratory): There is an additional pathway linking VD and elevated IL-6 in&#xD;
      PLWH which is independent of SIBO and bacterial translocation.&#xD;
&#xD;
      Aim 2: To determine whether the relationship between VD and SIBO is modified by the presence&#xD;
      of HIV-infection. HIV-infection results in disruption of the GI mucosal barrier,5 which could&#xD;
      make PLWH more vulnerable to adverse GI effects of VD. HIV-uninfected controls (N=100), age&#xD;
      and gender matched to the PLWH from Aim 1, will undergo the same assessment as the PLWH. The&#xD;
      study team will test for effect modification of the VD-SIBO relationship by HIV status, using&#xD;
      logistic regression to examine the interaction between VD and HIV.&#xD;
&#xD;
      Aim 3: To establish vagal pathways as a viable treatment target for individuals with&#xD;
      well-controlled HIV. PLWH with VD, SIBO and/or prolonged SBTT (N=96) will be identified from&#xD;
      the Aim 1 cohort. The first 86 eligible patients will be randomized to 8 weeks of&#xD;
      pyridostigmine versus placebo; the remaining 10 will receive 8 weeks of open-label&#xD;
      noninvasive vagal nerve stimulation (nVNS) to assess feasibility. All patients will then be&#xD;
      retested (AFTs, HBT, SmartPill, blood draw, stool samples and oral swabs).&#xD;
&#xD;
      Hypothesis 3a (primary): Eight weeks of low-dose pyridostigmine (30mg PO TID) will reduce&#xD;
      SIBO as compared to placebo in PLWH. Hypothesis 3b (exploratory): Non-invasive VNS is safe,&#xD;
      well tolerated and acceptable to PLWH.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2020</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Small bowel transit time (SBTT)</measure>
    <time_frame>5 years</time_frame>
    <description>Small bowel transit time (SBTT) measured by wireless motility capsule (wmc, smartpill)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastric pH measurement</measure>
    <time_frame>5 years</time_frame>
    <description>Gastric pH measurement measured by wireless motility capsule (wmc, smartpill)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hydrogen/methane breath testing (hbt)</measure>
    <time_frame>5 years</time_frame>
    <description>hydrogen/methane breath testing (hbt) to measure small intestinal bacterial overgrowth</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL6 measurement. [Time Frame: 5 years]</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>HIV</condition>
  <condition>Non-HIV</condition>
  <condition>Vagus Nerve Dysfunction</condition>
  <arm_group>
    <arm_group_label>PLWH</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>People living with HIV (HIV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy controls who do not have HIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pyridostigmine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PLWH on pyridostigmine 30mg PO TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PLWH on placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nVNS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PLWH to undergo non-invasive vagal nerve stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridostigmine</intervention_name>
    <description>Eight weeks of low-dose pyridostigmine</description>
    <arm_group_label>Pyridostigmine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>matching placebo x 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>non-invasive vagal nerve stimulation</intervention_name>
    <description>stimulation of the vagus nerve</description>
    <arm_group_label>nVNS</arm_group_label>
    <other_name>nVNS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
          -  Greater than or equal to18 years old (18 to 64 Years, 65 Years and Over)&#xD;
&#xD;
          -  Documentation of HIV-1 infection&#xD;
&#xD;
          -  Stable CART for greater or equal to 3 months&#xD;
&#xD;
          -  HIV-1 viral load &lt;100 copies/ml (within 3m)&#xD;
&#xD;
          -  No diagnosis known to cause autonomic or GI dysfunction other than HIV (e.g.&#xD;
             Parkinson's disease, diabetes, peptic ulcer disease, infectious diarrhea)&#xD;
&#xD;
          -  Willing to refrain from nicotine use for 24h prior to all testing&#xD;
&#xD;
          -  No contraindication to autonomic testing (e.g. uncontrolled glaucoma, heart rate not&#xD;
             under sinus control)&#xD;
&#xD;
          -  No medications with significant autonomic or GI effects (e.g. sympathomimetics,&#xD;
             prokinetics, anti-diarrheals, antibiotics)&#xD;
&#xD;
          -  Urine test negative for stimulants and opiates/opioids and pregnancy test (if&#xD;
             applicable)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dysphagia to food or pills&#xD;
&#xD;
          -  Known or suspected obstructive disease of the GI tract (e.g. bezoar, strictures,&#xD;
             fistulae, physiologic GI obstruction)&#xD;
&#xD;
          -  GI surgery within 3m, Crohn's disease, diverticulitis, any electromechanical medical&#xD;
             device (e.g. pacemaker, infusion pump).&#xD;
&#xD;
          -  Contraindication to pyridostigmine (e.g. mechanical intestinal or urinary obstruction,&#xD;
             hypersensitivity to pyridostigmine, cardiac arrhythmias, asthma, chronic obstructive&#xD;
             pulmonary disease); use of pyridostigmine within the past 6m.&#xD;
&#xD;
          -  History of intracranial aneurysm/hemorrhage, brain tumor, abnormal neck anatomy, or&#xD;
             implants or metal hardware near site of stimulation; exposure to VNS within the past&#xD;
             6m.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Robinson-Papp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandra Nmashie, MD</last_name>
    <phone>212-241-3193</phone>
    <email>Alexandra.nmashie@mssm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mary Catherine George, MM, PhD</last_name>
    <phone>212-241-0784</phone>
    <email>mary-catherine.george@mssm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Nmashie, MD</last_name>
      <phone>212-241-3193</phone>
      <email>Alexandra.nmashie@mssm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Catherine George, MM,PhD</last_name>
      <phone>212-241-0784</phone>
      <email>mary-catherine.george@mssm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jessica Robinson- Papp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Robinson-Papp J, Nmashie A, Pedowitz E, George MC, Sharma S, Murray J, Benn EKT, Lawrence SA, Machac J, Heiba S, Kim-Schulze S, Navis A, Roland BC, Morgello S. The effect of pyridostigmine on small intestinal bacterial overgrowth (SIBO) and plasma inflammatory biomarkers in HIV-associated autonomic neuropathies. J Neurovirol. 2019 Aug;25(4):551-559. doi: 10.1007/s13365-019-00756-9. Epub 2019 May 16.</citation>
    <PMID>31098925</PMID>
  </reference>
  <reference>
    <citation>Carod-Artal FJ. Infectious diseases causing autonomic dysfunction. Clin Auton Res. 2018 Feb;28(1):67-81. doi: 10.1007/s10286-017-0452-4. Epub 2017 Jul 20. Review.</citation>
    <PMID>28730326</PMID>
  </reference>
  <reference>
    <citation>Robinson-Papp J, Nmashie A, Pedowitz E, Benn EKT, George MC, Sharma S, Murray J, Machac J, Heiba S, Mehandru S, Kim-Schulze S, Navis A, Elicer I, Morgello S. Vagal dysfunction and small intestinal bacterial overgrowth: novel pathways to chronic inflammation in HIV. AIDS. 2018 Jun 1;32(9):1147-1156. doi: 10.1097/QAD.0000000000001802.</citation>
    <PMID>29596112</PMID>
  </reference>
  <reference>
    <citation>Paulon E, Nastou D, Jaboli F, Marin J, Liebler E, Epstein O. Proof of concept: short-term non-invasive cervical vagus nerve stimulation in patients with drug-refractory gastroparesis. Frontline Gastroenterol. 2017 Oct;8(4):325-330. doi: 10.1136/flgastro-2017-100809. Epub 2017 May 24.</citation>
    <PMID>29067158</PMID>
  </reference>
  <reference>
    <citation>Lerman I, Hauger R, Sorkin L, Proudfoot J, Davis B, Huang A, Lam K, Simon B, Baker DG. Noninvasive Transcutaneous Vagus Nerve Stimulation Decreases Whole Blood Culture-Derived Cytokines and Chemokines: A Randomized, Blinded, Healthy Control Pilot Trial. Neuromodulation. 2016 Apr;19(3):283-90. doi: 10.1111/ner.12398. Epub 2016 Mar 15.</citation>
    <PMID>26990318</PMID>
  </reference>
  <reference>
    <citation>Tarn J, Legg S, Mitchell S, Simon B, Ng WF. The Effects of Noninvasive Vagus Nerve Stimulation on Fatigue and Immune Responses in Patients With Primary Sj√∂gren's Syndrome. Neuromodulation. 2019 Jul;22(5):580-585. doi: 10.1111/ner.12879. Epub 2018 Oct 17.</citation>
    <PMID>30328647</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 17, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2020</study_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Jessica Robinson-Papp</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Small intestinal bacterial overgrowth</keyword>
  <keyword>People living with HIV</keyword>
  <keyword>HIV-associated autonomic neuropathy</keyword>
  <keyword>Distal symmetric polyneuropathy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyridostigmine Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Beginning 3 months and ending 5 years following article publication.</ipd_time_frame>
    <ipd_access_criteria>Anyone who wishes to access the data. Data will be published.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

